IN THE CLAIMS:

Claim 1 (cancelled).

Claim 2 (currently amended): A compound according to claim ~~1~~ 27 of the formula Ia:



(Ia)

wherein:

ring C^a is indolyl, indazolyl or azaindolyl;

R^{1a} is selected from oxo, hydroxy, C_{1-2}alkoxymethyl, amino, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, trifluoromethyl, cyano, nitro, C_{1-3}alkanoyl,

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27,

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27,

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27;

R^2 is as defined in claim ~~1~~ 27;

ma is 0, 1, 2 or 3;

Z^a is -O- or -S-; and

na is 0, 1 or 2;

with the proviso that at least one R^2 is selected from (i), (ii), (iii), (iv) or (v) as defined in claim ~~1~~ 27 in the definitions of R^2, and/or R^{1a} is selected from (i), (ii) and (iii) as defined herein,

or R^2 is 6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.

Claim 3 (original): A compound according to claim 2 wherein ma is 2.

Claim 4 (currently amended): A compound according to claim ~~1~~ 27 ~~or claim 2~~ wherein R^2 is selected from one of the five groups:

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27;

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27;

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27;

(iv) $Q^{28}C_{1-5}alkylX^1$-, $Q^{28}C_{2-5}alkenylX^1$- or $Q^{28}C_{2-5}alkynylX^1$- wherein Q^{28} and X^1 are as defined in claim ~~1~~ 27; and

(v) $Q^{29}C_{1-5}alkylX^1$-, $Q^{29}C_{2-5}alkenylX^1$- or $Q^{29}C_{2-5}alkynylX^1$- wherein Q^{29} and X^1 are as defined in claim ~~1~~ 27;

and/or R^2 represents methoxy, or R^2 represents 6,7-methylenedioxy or 6,7-ethylenedioxy.

Claim 5 (currently amended): A compound according to claim ~~1~~ 27 of the formula II:



(II)

wherein:

ring C^a is indolyl, indazolyl or azaindolyl;

R^{1a} is selected from oxo, hydroxy, C_{1-2}alkoxymethyl, amino, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, trifluoromethyl, cyano, nitro, C_{1-3}alkanoyl,

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27;

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27; and

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27;

R^{2a} and R^{2b}, are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, $-NR^{3a}R^{4a}$, ~~(~~wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl~~)~~,

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27,

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27,

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27,

(iv) $Q^{28}C_{1-5}alkylX^1$-, $Q^{28}C_{2-5}alkenylX^1$- or $Q^{28}C_{2-5}alkynylX^1$- wherein Q^{28} and X^1 are as defined in claim ~~1~~ 27 or

(v) $Q^{29}C_{1-5}alkylX^1$-, $Q^{29}C_{2-5}alkenylX^1$- or $Q^{29}C_{2-5}alkynylX^1$- wherein Q^{29} and X^1 are as defined in claim ~~1~~ 27,

or R^{2a} and R^{2b} together form 6,7-methylenedioxy or 6,7-ethylenedioxy;

Z^a is -O- or -S-;

and na is 0, 1 or 2;

with the proviso that at least one of R^{2a} and R^{2b} is selected from (i), (ii), (iii), (iv) or (v) as defined herein and/or R^{1a} is selected from (i), (ii) and (iii) as defined herein, or R^{2a} and R^{2b} together form 6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.

Claim 6 (original): A compound according to claim 5 wherein R^{1a} is fluoro or methyl.

Claim 7 (currently amended): A compound according to claim 5 ~~or claim 6~~ wherein Z^a is -O-.

Claim 8 (currently amended): A compound according to claim 5 ~~any one of claims 5, 6 and 7~~ wherein R^{2a} is methoxy and R^{2b} is selected from one of the five following groups:

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27;

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27;

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27;

(iv) $Q^{28}C_{1-5}alkylX^1$-, $Q^{28}C_{2-5}alkenylX^1$- or $Q^{28}C_{2-5}alkynylX^1$- wherein Q^{28} and X^1 are as defined in claim ~~1~~ 27; and

(v) $Q^{29}C_{1-5}alkylX^1$-, $Q^{29}C_{2-5}alkenylX^1$- or $Q^{29}C_{2-5}alkynylX^1$- wherein Q^{29} and X^1 are as defined in claim ~~1~~ 27.

Claim 9 (currently amended): A compound according to claim 5 ~~any one of claims 5, 6 and 7~~ wherein R^{2b} is methoxy and R^{2a} is selected from one of the five following groups:

(i) Q^1X^1 wherein Q^1 and X^1 are as defined in claim ~~1~~ 27;

(ii) $Q^{15}W^3$ wherein Q^{15} and W^3 are as defined in claim ~~1~~ 27;

(iii) $Q^{21}W^4C_{1-5}alkylX^1$- wherein Q^{21}, W^4 and X^1 are as defined in claim ~~1~~ 27;

(iv) $Q^{28}C_{1-5}alkylX^1$-, $Q^{28}C_{2-5}alkenylX^1$- or $Q^{28}C_{2-5}alkynylX^1$- wherein Q^{28} and X^1 are as defined in claim ~~1~~ 27; and

(v) $Q^{29}C_{1-5}alkylX^1$-, $Q^{29}C_{2-5}alkenylX^1$- or $Q^{29}C_{2-5}alkynylX^1$- wherein Q^{29} and X^1 are as defined in claim ~~1~~ 27.

Claim 10 (original): A compound according to any one of claims 2 to 8 wherein the ring C^a is indol-5-yl, indol-6-yl, 7-azaindol-5-yl, indazol-5-yl or indazol-6-yl.

Claim 11 (currently amended): A compound according to claim 5 of the formula IId:



(IId)

wherein:

M is -CH- or -N-;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is as defined in claim ~~1~~ 27 and Q^1 is selected from one of the following ten groups:

1) Q^2, ~~(~~ wherein Q^2 is a heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



,

which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, ~~C_{1-4}fluoroalkyl,~~ C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-4}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl and C_{1-4}fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}fluoroalkyl, C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-4}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl, C_{1-4}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl,

C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ring$D$- (wherein f is 0 or 1, g is 0 or 1 and ring D is selected from from pyrrolidinyl, piperidinyl, piperazinyl,

 and  ,

which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl));

2) C_{1-5}alkylW^1Q^2- (wherein W^1 represents -O-, -S-, -SO-, -SO_2-, -OC(O)-, -NQ^3C(O)-, -C(O)NQ^4-, -SO_2NQ^5-, -NQ^6SO_2- or –NQ^7- (wherein Q^3, Q^4, Q^5, Q^6 and Q^7 each independently represents hydrogen, C_{1-2}alkyl, C_{1-2}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein;
3) C_{1-5}alkylQ^2- (wherein Q^2 is as defined herein);
4) C_{2-5}alkenylQ^2- (wherein Q^2 is as defined herein);
5) C_{2-5}alkynylQ^2- (wherein Q^2 is as defined herein);
6) C_{1-4}alkylW^2C_{1-4}alkylQ^2- (wherein W^2 represents -O-, -S-, -SO-, -SO_2-, -NQ^8C(O)-, -C(O)NQ^9-, -SO_2NQ^{10}-, -$NQ^{11}SO_2$- or –NQ^{12}- (wherein Q^8, Q^9, Q^{10}, Q^{11} and Q^{12} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl) and Q^2 is as defined herein);
7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2- (wherein W^2 and Q^2 are as defined herein);
8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2- (wherein W^2 and Q^2 are as defined herein);
9) C_{1-4}alkylQ^{13}(C_{1-4}alkyl)$_j$(W^2)$_k$$Q^{14}$- (wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,

 and  ,

which heterocyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}fluoroalkyl, C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl,

C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-4}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl, C_{1-4}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD, (wherein f is 0 or 1, g is 0 or 1 and ring D is selected from pyrrolidinyl, piperidinyl, piperazinyl,

 and  ,

which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl), with the proviso that at least one of Q^{13} and Q^{14} bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, ~~C_{1-4}fluoroalkyl,~~ C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-4}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, C_{1-4}alkylsulphonyl and C_{1-4}fluoroalkylsulphonyl); and

10) C_{1-4}alkyl$Q^{13}$$C_{1-4}$alkanoyl$Q^{14n}$ wherein Q^{13} is as defined herein and Q^{14n} is selected from pyrrolidinyl, piperidinyl, piperazinyl,

 and  ,

wherein Q^{14n} is linked to C_{1-6}alkanoyl through a nitrogen atom;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

or a salt thereof.

Claim 12 (currently amended): A compound according to claim 11 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is selected from one of the following four groups:

1) Q^2, ~~wherein Q^2~~ is a heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,


and

,

which heterocyclic group bears one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl and C_{1-4}fluoroalkylsulphonyl;

2) C_{1-5}alkylQ^2, ~~wherein Q^2 is as defined herein~~;

3) C_{1-4}alkylW^2C_{1-4}alkylQ^2, ~~wherein W^2 is as defined in claim 11 and Q^2 is as defined herein~~;

4) C_{1-4}alkyl$Q^{13}(C_{1-4}alkyl)_j(W^2)_kQ^{14}$, ~~wherein W^2 is as defined in claim 11, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,~~


and

,

which heterocyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl,

C_{1-4}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl;

with the proviso that at least one of Q^{13} and Q^{14} bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-4}alkylsulphonyl and C_{1-4}fluoroalkylsulphonyl);

and additionally wherein any C_{1-5}alkyl, group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 13 (currently amended): A compound according to claim 5 of the formula IIh:



(IIh)

wherein:

M and T each independently represents a carbon atom or a nitrogen atom with the proviso that M and T cannot both be nitrogen atoms;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

either R^{2a} and R^{2b} form 6,7-methylenedioxy or one of R^{2a} and R^{2b} is methoxy and the other is selected from one of the following four groups:

(a) Q^1X^1- wherein X^1 is -O- and Q^1 is selected from one of the following three groups:

1) Q^2- (wherein Q^2 is a heterocyclic group selected from pyrrolidinyl, piperidinyl and piperazinyl, which heterocyclic group bears one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, ~~C_{1-6}fluoroalkyl,~~ C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl and C_{1-6}alkylsulphonyl;

2) C_{1-5}alkylQ^2- (wherein Q^2 is as defined herein~~)~~; and

3) C_{1-4}alkylW^2C_{1-4}alkylQ^2- (wherein W^2 represents -O- and Q^2 is as defined herein~~)~~;

and additionally wherein any C_{1-5}alkyl group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy~~)~~;

(b) $Q^{21}W^4C_{1-5}$alkylX^1- (wherein X^1 is -O-, W^4 is NQ^{26}- (wherein Q^{26} is hydrogen or C_{1-3}alkyl) and Q^{21} is C_{2-5}alkynyl~~)~~;

(c) $Q^{28}C_{1-5}$alkylX^1- wherein X^1 is -O- and Q^{28} is an imidazolidinyl group which bears two oxo substituents and one C_{1-6}alkyl group which C_{1-6}alkyl group bears a hydroxy substituent on the carbon atom which is linked to the imidazolidinyl group; and

(d) $Q^{29}C_{1-5}$alkylX^1- wherein X^1 is -O- and Q^{29} is a group 1,4-dioxa-8-azaspiro[4.5]dec-8-yl;

or a salt thereof.

Claim 14 (currently amended): A compound according to claim ~~1~~ 27 selected from:

4-(7-azaindol-5-yloxy)-7-methoxy-6-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)-quinazoline,

6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(7-azaindol-5-yloxy)-7-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{[(2*S*)-1-isobutyrylpyrrolidin-2-yl]methoxy}-6-methoxyquinazoline,

4-(7-azaindol-5-yloxy)-6-methoxy-7-[3-(4-carbamoylpiperazin-1-yl)propoxy]quinazoline,

6-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,

6-[(1-acetylpiperidin-4-yl)methoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,

7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,

4-(7-azaindol-5-yloxy)-7-[3-(4-carbamoylmethyl)piperazin-1-yl)propoxy]-6-methoxyquinazoline,

~~4-(7-azaindol-5-yloxy)-7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-6-methoxyquinazoline,~~

4-(7-azaindol-5-yloxy)-6-methoxy-7-[3-(4-prop-2-yn-1-ylpiperazin-1-yl)propoxy]-quinazoline,

7-[1-(*N*,*N*-dimethylaminoacetyl)piperidin-4-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol)-5-yloxy]-6-methoxyquinazoline,

and salts thereof.

Claim 15 (currently amended): A compound according to claim ~~14~~ 27 selected from:

6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxyquinazoline,

7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,

4-(7-azaindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)propoxy)-quinazoline,

4-(7-azaindol-5-yloxy)-6-methoxy-7-[2-(*N*-methyl-*N*-prop-2-yn-1-ylamino)ethoxy]-quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-7-methoxy-6-(3-(4-methylsulphonylpiperazin-1-yl)-propoxy)quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylsulphonylpiperazin-1-yl)-propoxy)quinazoline,

6-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoroindol-5-yloxy)-7-methoxyquinazoline,

7-[(1-acetylpiperidin-4-yl)methoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-[(2*S*)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-[(2*R*)-1-acetylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[1-(2,2,2-trifluoroethyl)-piperidin-4-ylmethoxy]quinazoline,~~

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]propoxy}quinazoline,~~

~~4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{3-[4-(2,2,2-trifluoroethyl)-piperazin-1-yl]ethoxy}quinazoline,~~

~~7-{2-[4-(2-fluoroethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,~~

7-{2-[2-(4-acetylpiperazin-1-yl)ethoxy]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)-oxy]-6-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-[(1-isobutyrylpiperidin-4-yl)methoxy]-6-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{[(2*R*)-1-isobutyrylpyrrolidin-2-yl]-methoxy}-6-methoxyquinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{[1-(methylsulfonyl)piperidin-4-yl]methoxy}quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{[(2*S*)-1-(methylsulfonyl)-pyrrolidin-2-yl]methoxy}quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{[(2*R*)-1-(methylsulfonyl)-pyrrolidin-2-yl]methoxy}quinazoline,

7-[3-(4-allylpiperazin-1-yl)propoxy]-4-(7-azaindol-5-yloxy)-6-methoxyquinazoline,

4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-{3-[4-(2-propynyl)piperazin-1-yl]-propoxy}quinazoline,

~~7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)-oxy]-6-methoxyquinazoline,~~

7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-(1*H*-indol-5-yloxy)-6-methoxyquinazoline,

7-[(2*S*)-1-carbamoylpyrrolidin-2-ylmethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-{3-[4-carbamoylpiperazin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-{3-[2,5-dioxo-4-(1-hydroxy-1-methylethyl)imidazolidin-1-yl]propoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yloxy]-6-methoxyquinazoline,

6-[(1-acetylpiperidin-4-yl)oxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxyquinazoline,

4-[(4-fluoro-1*H*-indol-5-yl)oxy]-7-methoxy-6-{[1-(methylsulphonyl)piperidin-4-yl]oxy}-quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-{2-[*N*-methyl-*N*-(2-propynyl)-amino]ethoxy}quinazoline,

7-[3-(4-acetylpiperazin-1-yl)propoxy]-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-quinazoline,

7-[3-(4-acetylpiperazin-1-yl)propoxy]-4-[(4-fluoro-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-[3-(4-carbamoylmethylpiperazin-1-yl)propoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)-oxy]-6-methoxyquinazoline,

~~7-{3-[4-(2-fluoroethyl)piperazin-1-yl]propoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)-oxy]quinazoline,~~

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-7-{(2*R*)-2-hydroxy-3-[4-prop-2-yn-1-yl-piperazin-1-yl]propoxy}-6-methoxyquinazoline,

7-{(2*R*)-3-[(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-{(2*R*)-3-[4-acetylpiperazin-1-yl]-2-hydroxypropoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

and salts thereof.

Claim 16 (currently amended): A compound according to claim ~~1~~ 27 which is 7-(3-(4-acetylpiperazin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline and salts thereof.

Claim 17 (currently amended): A compound according to claim ~~1~~ 27 which is 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline and salts thereof.

Claim 18 (currently amended): A compound according to claim ~~1~~ 27, claim 2 or claim 5 in the form of a pharmaceutically acceptable salt.

Claim 19 (currently amended): A process for the preparation of a compound according to claim ~~1~~ 27 of the formula I or salt thereof which comprises:

(a) the reaction of a compound of the formula III:



(III)

(wherein R^2 and m are as defined in claim ~~1~~ 27 and L^1 is a displaceable moiety), with a compound of the formula IV:



(IV)

(wherein ring C, R^1, Z and n are as defined in claim ~~1~~ 27);

(b) a compound of formula I and salts thereof wherein at least one R^2 is R^5X^1, Q^1X^1, $Q^{15}W^3$ or $Q^{21}W^4C_{1-5}alkylX^1$, wherein R^5, Q^1, Q^{15}, W^3, Q^{21} and W^4 are as defined in claim ~~1~~ 27, and X^1 is -O-, -S-, -OC(O)- or -NR^{10}-, (wherein R^{10} independently represents hydrogen,

C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) may be prepared by the reaction of a compound of the formula V:



(V)

(wherein ring C, Z, W^3, R^1, R^2 and n are as defined in claim 27 and X^1 is as defined in this section and s is an integer from 0 to 2,) with one of the compounds of the formulae VIa-d:

R^5-L^1 (VIa)

Q^1-L^1 (VIb)

Q^{15}-L^1 (VIc)

Q^{21}-W^4-C_{1-5}alkyl-L^1 (VId)

(wherein R^5, Q^1, Q^{15}, Q^{21} and W^4 are as defined in claim 27 and L^1 is as defined herein);

(c) a compound of the formula I and salts thereof wherein at least one R^2 is R^5X^1, Q^1X^1, $Q^{15}W^3$ or $Q^{21}W^4C_{1-5}$alkylX^1, wherein R^5, Q^1, Q^{15}, W^3, Q^{21} and W^4 are as defined in claim 27, and X^1 is -O-, -S-, -OC(O)- or -NR^{10}-, (wherein R^{10} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl,) may be prepared by the reaction of a compound of the formula VII:



(VII)

with one of the compounds of the formulae VIIIa-d:

R^5-X^1-H (VIIIa)

Q^1-X^1-H (VIIIb)

Q^{15}-W^3-H (VIIIc)

Q^{21}-W^4-C_{1-5}alkyl-X^1-H (VIIId)

(wherein s and L^1 are as defined herein, R^1, R^2, R^5, Q^1, Q^{15}, W^3, Q^{21}, W^4, ring C, Z and n are all as defined in claim 27 and X^1 is as defined in this section);

(d) a compound of the formula I and salts thereof wherein at least one R^2 is R^5X^1, Q^1X^1, $Q^{21}W^4C_{1-5}$alkylX^1, $Q^{28}C_{1-5}$alkylX^1 or $Q^{29}C_{1-5}$alkylX^1 wherein X^1 is as defined in claim 27, R^5 is C_{1-5}alkylR^{113}, wherein R^{113} is selected from one of the following nine groups:

1) $X^{19}C_{1-3}$alkyl, (wherein X^{19} represents -O-, -S-, $-SO_2$-, $-NR^{114}C(O)$- or $-NR^{115}SO_2$-, (wherein R^{114} and R^{115} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

2) $NR^{116}R^{117}$, (wherein R^{116} and R^{117} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl);

3) $X^{20}C_{1-5}$alkylX^5R^{22}, (wherein X^{20} represents -O-, -S-, $-SO_2$-, $-NR^{118}C(O)$-, $-NR^{119}SO_2$- or $-NR^{120}$-, (wherein R^{118}, R^{119}, and R^{120} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and X^5 and R^{22} are as defined in claim 27);

4) R^{28}, (wherein R^{28} is as defined in claim 27);

5) $X^{21}R^{29}$, (wherein X^{21} represents -O-, -S-, $-SO_2-$, $-NR^{121}C(O)-$, $-NR^{122}SO_2-$, or $-NR^{123}-$, (wherein R^{121}, R^{122}, and R^{123} which may be the same or different are each hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and R^{29} is as defined in claim 27); and

6) $X^{22}C_{1-3}$alkylR^{29}, (wherein X^{22} represents -O-, -S-, $-SO_2-$, $-NR^{124}C(O)-$, $-NR^{125}SO_2-$ or $-NR^{126}-$, (wherein R^{124}, R^{125} and R^{126} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl,) and R^{29} is as defined in claim 27);

7) R^{29}, (wherein R^{29} is as defined in claim 27);

8) $X^{22}C_{1-4}$alkylR^{28}, (wherein X^{22} and R^{28} are as defined in claim 27); and

9) $R^{54}(C_{1-4}alkyl)_q(X^9)_rR^{55}$, (wherein q, r, X^9, R^{54} and R^{55} are as defined in claim 27);

Q^1 is C_{1-5}alkylQ^{27} wherein Q^{27} is selected from:

10) W^1Q^2, (wherein W^1 and Q^2 are as defined in claim 27);

11) Q^2, (wherein Q^2 is as defined in claim 27);

12) W^2C_{1-4}alkylQ^2, (wherein W^2 and Q^2 are as defined in claim 27); and

13) $Q^{13}(C_{1-4}alkyl)_j(W^2)_kQ^{14}$, (wherein W^2, j, k, Q^{13} and Q^{14} are as defined in claim 27);

14) $Q^{13}(C_{1-4}$alkanoyl$)Q^{14n}$, (wherein Q^{13} and Q^{14n} are as defined in claim 27), and Q^{21}, W^4, Q^{28} and Q^{29} are as defined in claim 27,

may be prepared by reacting a compound of the formula IX:



(IX)

(wherein L^1 and s are as defined herein, X^1, R^1, R^2, ring C, Z and n are as defined in claim 1 27,) with one of the compounds of the formulae Xa-e:

R^{113}-H (Xa)

Q^{27}-H (Xb)

Q^{21}-W^4-H (Xc)

Q^{28}-H (Xd)

Q^{29}-H (Xe)

(wherein R^{113} and Q^{27} are as defined herein and Q^{21}, W^4, Q^{28} and Q^{29} are as defined in claim 1 27);

(e) a compound of the formula I or a salt thereof wherein one or more of the substituents $(R^2)_m$ is represented by $-NR^{127}R^{128}$, where one (and the other is hydrogen) or both of R^{127} and R^{128} are C_{1-3}alkyl, may be effected by the reaction of compounds of formula I wherein the substituent $(R^2)_m$ is an amino group and an alkylating agent; or

(f) a compound of the formula I or a salt thereof wherein X^1 is -SO- or $-SO_2-$ may be prepared by oxidation from the corresponding compound in which X^1 is -S- or -SO-;

and optionally forming ~~when a~~ salt of a compound of formula I ~~is required,~~ by reaction of the compound obtained with an acid or base ~~whereby to obtain the desired salt.~~

Claim 20 (currently amended): A pharmaceutical composition which comprises as active ingredient a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 27, claim 2 or claim 5 in association with a pharmaceutically acceptable excipient or carrier.

Claim 21 (cancelled).

Claim 22 (currently amended): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal ~~, such as a human being,~~ in need of such treatment which comprises administering to said animal an effective amount of

a compound according to claim ~~1~~ 27, claim 2 or claim 5, or a pharmaceutically acceptable salt thereof.

Claim 23 (original): The compound 7-benzyloxy-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline or a salt thereof.

Claim 24 (original): The compound 4-(4-fluoro-2-methylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline or a salt thereof.

Claim 25 (original): A process for the preparation of 5-bromo-7-azaindole comprising:

step 1: the reduction of 7-azaindole to give 7-azaindoline; followed by

step 2: the bromination of 7-azaindoline to give 5-bromo-7-azaindoline; followed by

step 3: the oxidation of 5-bromo-7-azaindoline to give 5-bromo-7-azaindole.

Claim 26 (original): A process for the production of 5-methoxy-7-azaindole comprising mixing a solution of the following materials in relative quantities according to the amounts given herein:

5-bromo-7-azaindole (8.6 g, 44 mmol), copper (I) bromide (12.6 g, 88 mmol) and sodium methoxide (100 g, 1.85 mol) in a mixture of "degassed" DMF (260 mls) and methanol (175 mls);

stirring the resulting mixture at ambient temperature in a nitrogen atmosphere; and then heating the mixture at reflux.

Claim 27 (new): A compound of the formula I:



(I)

wherein:

ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which optionally may contain 1-3 heteroatoms selected independently from O, N and S;

Z is -O- or -S-;

n is 0, 1, 2, 3, 4 or 5;

m is 0, 1, 2 or 3;

R^2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl,

$-NR^3R^4$, wherein R^3 and R^4, which may be the same or different, each represents hydrogen or C_{1-3}alkyl,

or R^5X^1- wherein X^1 represents a direct bond, -O-, $-CH_2-$, -OC(O)-, -C(O)-, -S-, -SO-, $-SO_2-$, $-NR^6C(O)-$, $-C(O)NR^7-$, $-SO_2NR^8-$, $-NR^9SO_2-$ or $-NR^{10}-$, wherein R^6, R^7, R^8, R^9 and R^{10} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^5 is selected from one of the following twenty-two groups:

1) hydrogen, oxiranylC_{1-4}alkyl or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkyl$X^2C(O)R^{11}$ wherein X^2 represents -O- or $-NR^{12}-$ in which R^{12} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{11} represents C_{1-3}alkyl, $-NR^{13}R^{14}$ or $-OR^{15}$, wherein R^{13}, R^{14} and R^{15} which may be the same or different each represents hydrogen, C_{1-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl;

3) $C_{1-5}alkylX^3R^{16}$ wherein X^3 represents -O-, -S-, -SO-, $-SO_2-$, -OC(O)-, $-NR^{17}C(O)-$, $-C(O)NR^{18}-$, $-SO_2NR^{19}-$, $-NR^{20}SO_2-$ or $-NR^{21}-$, wherein R^{17}, R^{18}, R^{19}, R^{20} and R^{21} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and R^{16} represents hydrogen, $C_{1-3}alkyl$, cyclopentyl, cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N,

which $C_{1-3}alkyl$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}alkoxy$ and

which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $di(C_{1-4}alkyl)amino$, $C_{1-4}alkylaminoC_{1-4}alkyl$, $di(C_{1-4}alkyl)aminoC_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, $di(C_{1-4}alkyl)aminoC_{1-4}alkoxy$ and a group $-(-O-)_f(C_{1-4}alkyl)_gringD$ wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from $C_{1-4}alkyl$;

4) $C_{1-5}alkylX^4C_{1-5}alkylX^5R^{22}$ wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, $-SO_2-$, $-NR^{23}C(O)-$, $-C(O)NR^{24}-$, $-SO_2NR^{25}-$, $-NR^{26}SO_2-$ or $-NR^{27}-$, wherein R^{23}, R^{24}, R^{25}, R^{26} and R^{27} each independently represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$ and R^{22} represents hydrogen, $C_{1-3}alkyl$ or $C_{1-3}alkoxyC_{2-3}alkyl$;

5) R^{28}, wherein R^{28} is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, $C_{1-4}cyanoalkyl$, $C_{1-4}alkyl$, $C_{1-4}hydroxyalkyl$, $C_{1-4}alkoxy$, $C_{1-4}alkoxyC_{1-4}alkyl$, $C_{1-4}alkylsulphonylC_{1-4}alkyl$, $C_{1-4}alkoxycarbonyl$, $C_{1-4}aminoalkyl$, $C_{1-4}alkylamino$, $di(C_{1-4}alkyl)amino$, $C_{1-4}alkylaminoC_{1-4}alkyl$, $di(C_{1-4}alkyl)aminoC_{1-4}alkyl$, $C_{1-4}alkylaminoC_{1-4}alkoxy$, $di(C_{1-4}alkyl)aminoC_{1-4}alkoxy$ and a group $-(-O-)_f(C_{1-4}alkyl)_gringD$ wherein f is 0

or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

6) C_{1-5}alkylR^{28}, wherein R^{28} is as defined herein;

7) C_{2-5}alkenylR^{28}, wherein R^{28} is as defined herein;

8) C_{2-5}alkynylR^{28}, wherein R^{28} is as defined herein;

9) R^{29}, wherein R^{29} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, $-C(O)NR^{30}R^{31}$, $-NR^{32}C(O)R^{33}$ wherein R^{30}, R^{31}, R^{32} and R^{33}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and a group $-(-O-)_f(C_{1-4}\text{alkyl})_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

10) C_{1-5}alkylR^{29}, wherein R^{29} is as defined herein;

11) C_{2-5}alkenylR^{29}, wherein R^{29} is as defined herein;

12) C_{2-5}alkynylR^{29}, wherein R^{29} is as defined herein;

13) C_{1-5}alkylX^6R^{29} wherein X^6 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{34}C(O)-$, $-C(O)NR^{35}-$, $-SO_2NR^{36}-$, $-NR^{37}SO_2-$ or $-NR^{38}-$, wherein R^{34}, R^{35}, R^{36}, R^{37} and R^{38} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{29} is as defined herein;

14) C_{2-5}alkenylX^7R^{29} wherein X^7 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{39}C(O)-$, $-C(O)NR^{40}-$, $-SO_2NR^{41}-$, $-NR^{42}SO_2-$ or $-NR^{43}-$, wherein R^{39}, R^{40}, R^{41}, R^{42} and R^{43} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{29} is as defined herein;

15) C_{2-5}alkynylX^8R^{29} wherein X^8 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{44}C(O)-$, $-C(O)NR^{45}-$, $-SO_2NR^{46}-$, $-NR^{47}SO_2-$ or $-NR^{48}-$, wherein R^{44}, R^{45}, R^{46}, R^{47} and R^{48} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{29} is as defined herein;

16) C_{1-4}alkylX^9C_{1-4}alkylR^{29} wherein X^9 represents -O-, -S-, -SO-, $-SO_2-$, $-NR^{49}C(O)-$, $-C(O)NR^{50}-$, $-SO_2NR^{51}-$, $-NR^{52}SO_2-$ or $-NR^{53}-$, wherein R^{49}, R^{50}, R^{51}, R^{52} and R^{53} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{29} is as defined herein;

17) C_{1-4}alkylX^9C_{1-4}alkylR^{28}, wherein X^9 and R^{28} are as defined herein;

18) C_{2-5}alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

19) C_{2-5}alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

20) C_{2-5}alkenylX^9C_{1-4}alkylR^{28}, wherein X^9 and R^{28} are as defined herein;

21) C_{2-5}alkynylX^9C_{1-4}alkylR^{28}, wherein X^9 and R^{28} are as defined herein; and

22) C_{1-4}alkyl$R^{54}(C_{1-4}\text{alkyl})_q(X^9)_rR^{55}$ wherein X^9 is as defined herein, q is 0 or 1, r is 0 or 1, and R^{54} and R^{55} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group $-(\text{-O-})_f(C_{1-4}\text{alkyl})_g$ringD wherein f is 0

or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl, with the proviso that R^{54} cannot be hydrogen;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in R^5X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

R^1 represents hydrogen, oxo, halogeno, hydroxy, C_{1-4}alkoxy, C_{1-4}alkyl, C_{1-4}alkoxymethyl, C_{1-4}alkanoyl, C_{1-4}haloalkyl, cyano, amino, C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-3}alkanoyloxy, nitro, C_{1-4}alkanoylamino, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulphanyl, C_{1-4}alkylsulphinyl, C_{1-4}alkylsulphonyl, carbamoyl, N-C_{1-4}alkylcarbamoyl, N,N-di(C_{1-4}alkyl)carbamoyl, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl, N,N-di(C_{1-4}alkyl)aminosulphonyl, N-(C_{1-4}alkylsulphonyl)amino, N-(C_{1-4}alkylsulphonyl)-N-(C_{1-4}alkyl)amino, N,N-di(C_{1-4}alkylsulphonyl)amino, a C_{3-7}alkylene chain joined to two ring C carbon atoms, C_{1-4}alkanoylaminoC_{1-4}alkyl, carboxy

or a group $R^{56}X^{10}$ wherein X^{10} represents a direct bond, -O-, -CH_2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO_2-, -NR^{57}C(O)-, -C(O)NR^{58}-, -SO_2NR^{59}-, -$NR^{60}SO_2$- or -NR^{61}-, wherein R^{57}, R^{58}, R^{59}, R^{60} and R^{61} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{56} is selected from one of the following twenty-two groups:

1) hydrogen, oxiranylC_{1-4}alkyl or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;

2) C_{1-5}alkylX^{11}C(O)R^{62} wherein X^{11} represents -O- or -NR^{63}-,in which R^{63} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{62} represents C_{1-3}alkyl, -$NR^{64}R^{65}$ or -OR^{66}, wherein R^{64}, R^{65} and R^{66} which may be the same or different each represents hydrogen, C_{1-5}alkyl or C_{1-3}alkoxyC_{2-3}alkyl;

3) C_{1-5}alkyl$X^{12}R^{67}$ wherein X^{12} represents -O-, -S-, -SO-, -SO_2-, -OC(O)-, -NR^{68}C(O)-, -C(O)NR^{69}-, -SO_2NR^{70}-, -$NR^{71}SO_2$- or -NR^{72}-, wherein R^{68}, R^{69}, R^{70}, R^{71} and R^{72} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{67} represents hydrogen, C_{1-3}alkyl, cyclopentyl,

cyclohexyl or a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

4) C_{1-5}alkyl$X^{13}C_{1-5}$alkyl$X^{14}R^{73}$ wherein X^{13} and X^{14} which may be the same or different are each -O-, -S-, -SO-, -SO_2-, -$NR^{74}C(O)$-, -$C(O)NR^{75}$-, -SO_2NR^{76}-, -$NR^{77}SO_2$- or -NR^{78}-, wherein R^{74}, R^{75}, R^{76}, R^{77} and R^{78} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and R^{73} represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl;

5) R^{79}, wherein R^{79} is a 5-6-membered saturated heterocyclic group, linked via carbon or nitrogen, with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

6) C_{1-5}alkylR^{79}, wherein R^{79} is as defined herein;

7) C_{2-5}alkenylR^{79}, wherein R^{79} is as defined herein;

8) C_{2-5}alkynylR^{79}, wherein R^{79} is as defined herein;

9) R^{80}, wherein R^{80} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group, linked via carbon or nitrogen, with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from oxo, hydroxy, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)$NR^{81}R^{82}$, -NR^{83}C(O)R^{84} wherein R^{81}, R^{82}, R^{83} and R^{84}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl) and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

10) C_{1-5}alkylR^{80}, wherein R^{80} is as defined herein;

11) C_{2-5}alkenylR^{80}, wherein R^{80} is as defined herein;

12) C_{2-5}alkynylR^{80}, wherein R^{80} is as defined herein;

13) C_{1-5}alkyl$X^{15}R^{80}$ wherein X^{15} represents -O-, -S-, -SO-, -SO_2-, -NR^{85}C(O)-, -C(O)NR^{86}-, -SO_2NR^{87}-, -$NR^{88}SO_2$- or -NR^{89}-, wherein R^{85}, R^{86}, R^{87}, R^{88} and R^{89} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and R^{80} is as defined herein;

14) C_{2-5}alkenyl$X^{16}R^{80}$ wherein X^{16} represents -O-, -S-, -SO-, -SO_2-, -NR^{90}C(O)-, -C(O)NR^{91}-, -SO_2NR^{92}-, -$NR^{93}SO_2$- or -NR^{94}-, wherein R^{90}, R^{91}, R^{92}, R^{93} and R^{94} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and R^{80} is as defined herein;

15) C_{2-5}alkynyl$X^{17}R^{80}$ wherein X^{17} represents -O-, -S-, -SO-, -SO_2-, -NR^{95}C(O)-, -C(O)NR^{96}-, -SO_2NR^{97}-, -$NR^{98}SO_2$- or -NR^{99}-, wherein R^{95}, R^{96}, R^{97}, R^{98} and R^{99} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and R^{80} is as defined herein;

16) C_{1-4}alkyl$X^{18}C_{1-4}$alkylR^{80} wherein X^{18} represents -O-, -S-, -SO-, -SO_2-, -NR^{100}C(O)-, -C(O)NR^{101}-, -SO_2NR^{102}-, -$NR^{103}SO_2$- or -NR^{104}-, wherein R^{100},

R^{101}, R^{102}, R^{103} and R^{104} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and R^{80} is as defined herein;

17) C_{1-4}alkyl$X^{18}C_{1-4}$alkylR^{79}, wherein X^{18} and R^{79} are as defined herein;

18) C_{2-5}alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

19) C_{2-5}alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C_{1-4}alkylamino, N,N-di(C_{1-4}alkyl)amino, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl and N,N-di(C_{1-4}alkyl)aminosulphonyl;

20) C_{2-5}alkenyl$X^{18}C_{1-4}$alkylR^{79}, wherein X^{18} and R^{79} are as defined herein;

21) C_{2-5}alkynyl$X^{18}C_{1-4}$alkylR^{79}, wherein X^{18} and R^{79} are as defined herein; and

22) C_{1-4}alkyl$R^{105}(C_{1-4}alkyl)_x(X^{18})_yR^{106}$ wherein X^{18} is as defined herein, x is 0 or 1, y is 0 or 1, and R^{105} and R^{106} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl, with the proviso that R^{105} cannot be hydrogen;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in $R^{56}X^{10}$- which is linked to X^{10} may bear one or more substituents selected from hydroxy, halogeno and amino;

with the proviso that one or more R^1 and/or one or more R^2 are selected from one of the following five groups:

(i) Q^1X^1- wherein X^1 is as defined herein and Q^1 is selected from one of the following ten groups:

1) Q^2, wherein Q^2 is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group may optionally bear a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl;

2) C_{1-5}alkylW^1Q^2 wherein W^1 represents -O-, -S-, -SO-, $-SO_2$-, -OC(O)-, $-NQ^3C(O)$-, $-C(O)NQ^4$-, $-SO_2NQ^5$-, $-NQ^6SO_2$- or $-NQ^7$-, wherein Q^3, Q^4, Q^5, Q^6 and Q^7 each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl and Q^2 is as defined herein;

3) C_{1-5}alkylQ^2, wherein Q^2 is as defined herein;

4) C_{2-5}alkenylQ^2, wherein Q^2 is as defined herein;

5) C_{2-5}alkynylQ^2, wherein Q^2 is as defined herein;

6) C_{1-4}alkylW^2C_{1-4}alkylQ^2 wherein W^2 represents -O-, -S-, -SO-, $-SO_2$-, $-NQ^8C(O)$-, $-C(O)NQ^9$-, $-SO_2NQ^{10}$-, $-NQ^{11}SO_2$- or $-NQ^{12}$-, wherein Q^8, Q^9, Q^{10}, Q^{11} and Q^{12} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl and Q^2 is as defined herein;

7) C_{2-5}alkenylW^2C_{1-4}alkylQ^2, wherein W^2 and Q^2 are as defined herein;

8) C_{2-5}alkynylW^2C_{1-4}alkylQ^2, wherein W^2 and Q^2 are as defined herein;

9) C_{1-4}alkyl$Q^{13}(C_{1-4}$alkyl$)_j(W^2)_kQ^{14}$ wherein W^2 is as defined herein, j is 0 or 1, k is 0 or 1, and Q^{13} and Q^{14} are each independently selected from hydrogen, C_{1-3}alkyl, cyclopentyl, cyclohexyl and a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C_{1-3}alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C_{1-4}alkoxy and which cyclic group may bear 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated

heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl, with the provisos that Q^{13} cannot be hydrogen and one or both of Q^{13} and Q^{14} must be a 5-6-membered saturated or partially unsaturated heterocyclic group as defined herein which heterocyclic group bears at least one substituent selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl and C_{1-6}fluoroalkylsulphonyl and which heterocyclic group optionally bears 1 or 2 further substituents selected from those defined herein;

10) C_{1-4}alkyl$Q^{13}$$C_{1-4}$alkanoyl$Q^{14n}$ wherein Q^{13} is as defined herein and is not hydrogen and Q^{14n} is a 5-6-membered saturated or partially unsaturated heterocyclic group containing at least one nitrogen atom and optionally containing a further nitrogen atom wherein Q^{14n} is linked to C_{1-6}alkanoyl through a nitrogen atom and wherein Q^{14n} optionally bears 1, 2 or 3 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear one or more substituents selected from C_{1-4}alkyl;

and additionally wherein any C_{1-5}alkyl, C_{2-5}alkenyl or C_{2-5}alkynyl group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

(ii) $Q^{15}W^3$- wherein W^3 represents $-NQ^{16}C(O)$-, $-C(O)NQ^{17}$-, $-SO_2NQ^{18}$-, $-NQ^{19}SO_2$- or $-NQ^{20}$-, wherein Q^{16}, Q^{17}, Q^{18}, Q^{19} and Q^{20} each independently represents C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-4}haloalkyl, and Q^{15} is C_{2-5}alkenyl or C_{2-5}alkynyl;

(iii) $Q^{21}W^4C_{1-5}$alkylX^1- wherein W^4 represents $-NQ^{22}C(O)$-, $-C(O)NQ^{23}$-, $-SO_2NQ^{24}$-, $-NQ^{25}SO_2$- or $-NQ^{26}$-, wherein Q^{22}, Q^{23}, Q^{24}, Q^{25} and Q^{26} each independently represents hydrogen, C_{1-3}alkyl, C_{1-3}alkoxyC_{2-3}alkyl, C_{2-5}alkenyl, C_{2-5}alkynyl or C_{1-4}haloalkyl, and Q^{21} represents C_{2-5}alkenyl or C_{2-5}alkynyl, and X^1 is as defined herein;

(iv) $Q^{28}C_{1-5}$alkylX^1-, $Q^{28}C_{2-5}$alkenylX^1- or $Q^{28}C_{2-5}$alkynylX^1- wherein X^1 is as defined herein and Q^{28} is an imidazolidinyl group which bears two oxo substituents and one C_{1-6}alkyl or C_{3-10}cycloalkyl group which C_{1-6}alkyl or C_{3-10}cycloalkyl group may bear a hydroxy substituent on the carbon atom which is linked to the imidazolidinyl group, and wherein the C_{1-5}alkyl, C_{1-5}alkenyl or C_{1-5}alkynyl linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino; and

(v) $Q^{29}C_{1-5}$alkylX^1-, $Q^{29}C_{2-5}$alkenylX^1- or $Q^{29}C_{2-5}$alkynylX^1- wherein X^1 is as defined herein, the C_{1-5}alkyl, C_{1-5}alkenyl or C_{1-5}alkynyl linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino and Q^{29} is a group 1,4-dioxa-8-azaspiro[4.5]dec-8-yl, which may be represented:


;

or R^1 may be selected from any of the groups defined herein for R^1 and R^2 is 6,7-methylenedioxy or 6,7-ethylenedioxy;

or a salt thereof.